Bristol-Myers Squibb Company BMY and Otsuka America Pharmaceutical,
Inc. today announced that the U.S. Food and Drug Administration (FDA) has
approved an update to the Sprycel (dasatinib) product labeling. The labeling
now includes three-year efficacy and safety data in patients with newly
diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
(CML) in chronic phase (CP) and five-year data in CP Ph+ CML patients who are
resistant or intolerant to Gleevec^®1 (imatinib mesylate).
Sprycel is a kinase inhibitor indicated for the treatment of adults with newly
diagnosed CP Ph+ CML. The effectiveness of Sprycel is based on cytogenetic
response and major molecular response rates. The trial is ongoing and further
data will be required to determine long-term outcome. Sprycel is also
indicated for Ph+ CML in all phases (chronic, accelerated, or myeloid or
lymphoid blast) with resistance or intolerance to prior therapy including
imatinib and Ph+ acute lymphoblastic leukemia (ALL) with resistance or
intolerance to prior therapy.
“These longer-term data add to the growing body of research around the safety
and efficacy of Sprycel in first-line CP Ph+ CML patients and those who are
resistant or intolerant to imatinib,” said Neil Shah, MD, PhD, Associate
Professor, Division of Hematology/Oncology, University of California, San
Francisco. “CML requires ongoing treatment and assessment of treatment
milestones in order to manage the disease properly. Given the chronic nature
of CML, these long-term data are particularly important for patient care.”
“Bristol-Myers Squibb remains committed to helping patients with newly
diagnosed and imatinib-resistant or intolerant CP Ph+ CML through treatment
with Sprycel, a convenient once-daily treatment option,” said Laura Bessen,
MD, vice president and head of U.S. Medical, Bristol-Myers Squibb. “The
longer-term safety and efficacy data that have been added to the Sprycel^®
(dasatinib) U.S. labeling underscore this longstanding commitment. Since the
initial FDA approval in 2006, more than 175,000 Sprycel prescriptions have
been written in the U.S.”
“We are fortunate to be living at a time when, for many patients, CML can
often be managed as a chronic disease, thanks to treatments like Sprycel,”
said Greg Stephens, executive director, National CML Society. “As patients
continue to benefit from these treatments, understanding their safety and
effectiveness over time becomes increasingly important and may help inform the
decisions of healthcare providers as to which therapy they choose.”
Sprycel Demonstrated Higher Response than Imatinib in Newly-diagnosed Patients
Information added to the Sprycel label in the first-line CP Ph+ CML setting is
based on three-year data from DASISION (Dasatinib versus Imatinib Study in
Treatment-Naïve CML Patients), an open-label, randomized, Phase 3
international trial. In the study, Sprycel demonstrated superior efficacy as
defined by higher molecular (major molecular response^2 or MMR) and confirmed
cytogenetic response rates (CCyR^3) by 12 months, compared to imatinib.
In DASISION, 77% [95% CI, 71% - 82%] of patients treated with Sprycel (n=259)
vs. 66% [95%, CI, 60% - 72%] of patients treated with imatinib (n=260)
achieved the primary endpoint of confirmed CCyR (defined as two consecutive
assessments of CCyR at least 28 days apart) by 12 months (p=0.007). After 36
months follow-up, median time to confirmed CCyR was 3.1 months in 214 Sprycel
responders and 5.8 months in 201 imatinib responders. In the long-term (by 3
years), confirmed CCyR rates continued to increase (83% Sprycel vs. 77%
imatinib).^4
Sprycel patients were more likely than imatinib patients to achieve MMR^2, a
measure of deeper treatment response, by year one (52% [95% CI, 46% - 58%] vs.
34% [95% CI, 28% - 40%], respectively; p<0.0001). ^ In the long ^ term (by
year 3), MMR at any time was higher for Sprycel than imatinib (69% [95% CI,
63% - 75%] vs. 56% [95% CI, 50% - 62%], respectively).^4 The study also showed
higher MMR rates at any time with Sprycel, across all Hasford^5 risk groups
vs. imatinib (low risk: 81% vs. 64%; medium risk: 64% vs. 56%; and high risk:
61% vs. 42%). ^ In patients treated with Sprycel^® (dasatinib) the vast
majority did not transform to accelerated or blast phase CML by three years
(3% with Sprycel and 5% with imatinib).
The most frequently reported serious adverse reactions in patients with newly
diagnosed CP Ph+ CML included pleural effusion (4%), hemorrhage (2%),
congestive heart failure (1%), pulmonary hypertension (1%), and pyrexia (1%).
^ The most frequently reported adverse reactions reported in ≥10% of patients
with newly diagnosed CP Ph+ CML included myelosuppression, fluid retention
events (pleural effusion and superficial localized edema), diarrhea, headache,
musculoskeletal pain, rash, and nausea. ^ The safety and efficacy evaluation
in this trial is ongoing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in